Sage Journals: Discover world-class research

Abstract

Clonality analysis of viral vector-transduced cell populations represents a convincing approach to dissect the physiology of tissue and organ regeneration, to monitor the fate of individual gene-corrected cells in vivo, and to assess vector biosafety. With the decoding of mammalian genomes and the introduction of next-generation sequencing technologies, the demand for automated bioinformatic analysis tools that can rapidly process and annotate vector integration sites is rising. Here, we provide a publicly accessible, graphical user interface-guided automated bioinformatic high-throughput integration site analysis pipeline. Its performance and key features are illustrated on pyrosequenced linear amplification-mediated PCR products derived from one patient previously enrolled in the first lentiviral vector clinical gene therapy study. Analysis includes trimming of vector genome junctions, alignment of genomic sequence fragments to the host genome for the identification of integration sites, and the annotation of nearby genomic elements. Most importantly, clinically relevant features comprise the determination of identical integration sites with respect to different time points or cell lineages, as well as the retrieval of the most prominent cell clones and common integration sites. The resulting output is summarized in tables within a convenient spreadsheet and can be further processed by researchers without profound bioinformatic knowledge.

Arens and colleagues provide an automated, high-throughput, publicly accessible, graphical user interface-guided bioinformatic tool for analysis of viral vector integration sites. Analyses include trimming of vector genome junctions, alignment of genomic sequence fragments to the host genome for the identification of clinically relevant integration sites, and the annotation of nearby genomic elements.

Get full access to this article

View all access options for this article.

References

Abel

, Deichmann

, Bartholomae

et al. 2007. Real-time definition of non-randomness in the distribution of genomic events. PLoS One, 2:e570.

Abel

, Deichmann

, Nowrouzi

et al. 2011. Analyzing the number of common integration sites of viral vectors—new methods and computer programs. PLoS One, 6:e24247.

Aiuti

, Slavin

, Aker

et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296:2410–2413.

Aiuti

, Cattaneo

, Galimberti

et al. 2009. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360:447–458.

Appelt

J.U.

, Giordano

F.A.

, Ecker

et al. 2009. QuickMap: A public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther., 16:885–893.

Bartholomae

C.C.

, Arens

, Balaggan

K.S.

et al. 2011. Lentiviral vector integration profiles differ in rodent postmitotic tissues. Mol. Ther., 19:703–710.

Bessereau

J.-L.

2006. Transposons in C. elegans. WormBook. The C. elegans Research Community, ed. http://www.wormbook.org/chapters/www_transposons/transposons.html

Bianchi

, Hakkim

, Brinkmann

et al. 2009. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood, 114:2619–2622.

Biffi

, Bartolomae

C.C.

, Cesana

et al. 2011. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood, 117:5332–5339.

10.

Boztug

, Schmidt

, Schwarzer

et al. 2010. Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med., 363:1918–1927.

11.

Cartier

, Hacein-Bey-Abina

, Bartholomae

C.C.

et al. 2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.

12.

Cavazzana-Calvo

, Payen

, Negre

et al. 2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–322.

13.

Cavazzana-Calvo

, Fischer

, Bushman

F.D.

et al. 2011. Is normal hematopoiesis maintained solely by long-term multipotent stem cells? Blood, 117:4420–4424.

14.

Copeland

N.G.

, Jenkins

N.A.

2010. Harnessing transposons for cancer gene discovery. Nat. Rev Cancer, 10:696–706.

15.

de Ridder

, Uren

, Kool

et al. 2006. Detecting statistically significant common insertion sites in retroviral insertional mutagenesis screens. PLoS Comput. Biol., 2:e166.

16.

Dieter

S.M.

, Ball

C.R.

, Hoffmann

C.M.

et al. 2011. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell, 9:357–365.

17.

Gabriel

, Eckenberg

, Paruzynski

et al. 2009. Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med., 15:1431–1436.

18.

Gabriel

, Lombardo

, Arens

et al. 2011. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nature Biotechnol., 29:816–823.

19.

Gaspar

H.B.

, Parsley

K.L.

, Howe

et al. 2004. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet, 364:2181–2187.

20.

Gillet

N.A.

, Malani

, Melamed

et al. 2011. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood, 117:3113–3122.

21.

Glimm

, Schmidt

, Fischer

et al. 2005. Efficient marking of human cells with rapid but transient repopulating activity in autografted recipients. Blood, 106:893–898.

22.

Grez

, Reichenbach

, Schwable

et al. 2011. Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol. Ther., 19:28–35.

23.

Hacein-Bey-Abina

, Le Deist

, Carlier

et al. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med., 346:1185–1193.

24.

Hacein-Bey-Abina

, Von Kalle

, Schmidt

et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302:415–419.

25.

Hacein-Bey-Abina

, Garrigue

, Wang

G.P.

et al. 2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.

26.

Hacein-Bey-Abina

, Hauer

, Lim

et al. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med., 363:355–364.

27.

Hawkins

T.B.

, Dantzer

, Peters

et al. 2011. Identifying viral integration sites using SeqMap 2.0. Bioinformatics, 27:720–722.

28.

Howe

S.J.

, Mansour

M.R.

, Schwarzwaelder

et al. 2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118:3143–3150.

29.

Kang

H.J.

, Bartholomae

C.C.

, Paruzynski

et al. 2011. Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol. Ther., 19:2092–2101.

30.

Karolchik

, Hinrichs

A.S.

, Furey

T.S.

et al. 2004. The UCSC Table Browser data retrieval tool. Nucleic Acids Res., 32:D493–D496.

31.

Kent

W.J.

2002. BLAT—the BLAST-like alignment tool. Genome Res., 12:656–664.

32.

Lemischka

I.R.

, Jordan

C.T.

2001. The return of clonal marking sheds new light on human hematopoietic stem cells. Nat. Immunol., 2:11–12.

33.

Margulies

, Egholm

, Altman

W.E.

et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature, 437:376–380.

34.

Matrai

, Cantore

, Bartholomae

C.C.

et al. 2011. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology, 53:1696–1707.

35.

Mitchell

R.S.

, Beitzel

B.F.

, Schroder

A.R.

et al. 2004. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol., 2:e234.

36.

Mueller

P.R.

, Wold

1989. In vivo footprinting of a muscle specific enhancer by ligation mediated PCR. Science, 246:780–786.

37.

Newman

, Lardelli

2010. A hyperactive Sleeping Beauty transposase enhances transgenesis in zebrafish embryos. BMC Res. Notes, 3:282.

38.

Noonan

J.P.

, Coop

, Kudaravalli

et al. 2006. Sequencing and analysis of Neanderthal genomic DNA. Science, 314:1113–1118.

39.

Ott

M.G.

, Schmidt

, Schwarzwaelder

et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12:401–409.

40.

Paruzynski

, Arens

, Gabriel

et al. 2010. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc., 5:1379–1395.

41.

Paruzynski

, Boztug

, Ball

et al. 2011. Molecular follow-up of the German WAS clinical gene therapy trial [abstract 343] Mol. Ther., 19:S133.

42.

Pruitt

K.D.

, Tatusova

, Klimke

et al. 2009. NCBI Reference Sequences: Current status, policy and new initiatives. Nucleic Acids Res., 37:D32–D36.

43.

Schmidt

, Hacein-Bey-Abina

, Wissler

et al. 2005. Clonal evidence for the transduction of CD34⁺ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood, 105:2699–2706.

44.

Schmidt

, Schwarzwaelder

, Bartholomae

et al. 2007. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR) Nat. Methods, 4:1051–1057.

45.

Schroder

A.R.

, Shinn

, Chen

et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell, 110:521–529.

46.

Silver

, Keerikatte

1989. Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J. Virol., 63:1924–1928.

47.

Stein

, Ott

M.G.

, Schultze-Strasser

et al. 2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.

48.

Suzuki

, Shen

, Akagi

et al. 2002. New genes involved in cancer identified by retroviral tagging. Nat. Genet., 32:166–174.

49.

, Li

, Crise

et al. 2003. Transcription start regions in the human genome are favored targets for MLV integration. Science, 300:1749–1751.

50.

Ylä-Herttuala

2011. Gene therapy moves forward in 2010. Mol. Ther., 19:219–220.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

2.66 MB

Bioinformatic Clonality Analysis of Next-Generation Sequencing-Derived Viral Vector Integration Sites

Abstract

Get full access to this article

References

Supplementary Material